Autifony Therapeutics extends Series A with £8 million for hearing disorders and schizophrenia clinical trials

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced the closing of an £8 million extension to its Series A funding round.

Read More